P004 Updates in Oncodermatology
DESCRIPTION
This session will be directed towards general dermatologists wanting more familiarity with Oncodermatology. It will be divided into three sections on immunotherapy, targeted inhibitors including EGFR inhibitors, and cutaneous considerations in patients with hematologic malignancies. The immunotherapy section will cover what immunotherapy is as well as diagnosing and managing cutaneous immune related adverse events. In the targeted therapy section, we will review EGFR inhibitor toxicities and management. In the last section, learners will become comfortable with cutaneous diagnoses unique to patients with hematologic malignancies such as GVHD. Learning will be substantiated with representative cases as well as relevant literature.
LEARNING OBJECTIVES
Describe, diagnose, and manage the cutaneous adverse events that occur in patients on PD1, PDL-1, CTLA-4 immunotherapies
Describe, diagnose, and manage the cutaneous toxicities associated with EGFR inhibitors and other targeted cancer therapeutics
Identify and treat the unique skin conditions relevant to patients with hematologic malignancies
SCHEDULE
5:00 PM
Immunotherapy and Cutaneous Immune Related Adverse Events
Noah Io Hornick, MD, PhD, FAAD
5:40 PM
Update on Cutaneous Reactions to Targeted Cancer Therapy
Fiorinda Fiona Muhaj, MD, FAAD
6:20 PM
Cutaneous Considerations in Patients with Hematologic Malignancies
Connie Shi, MD, FAAD
SPEAKERS
Noah Io Hornick, MD, PhD, FAAD
Oregon Health & Science University
Fiorinda Fiona Muhaj, MD, FAAD
Connie Shi, MD, FAAD
Brigham and Women's Hospital / Dana Farber Cancer Instititute
SPEAKER DISCLOSURES
Noah Io Hornick, MD, PhD, FAAD
Shook Hardy & Bacon – Consultant (1099 relationship)(Fees); Therakos, Inc. – Data Safety Monitoring Board(Fees);
Fiorinda Fiona Muhaj, MD, FAAD
No financial relationships exist with ineligible companies.
Connie Shi, MD, FAAD
VisualDx – Consultant (1099 relationship)(Honoraria);